1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 15 DECEMBER 2014

CNS Drug News 15 DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Unmet Medical Needs A Focus Of CNS Segment In 2014
Industry Brief - Phase III Trial Of Acorda's CVT-301 In PD Initiated
Industry Brief - Teikoku Reports Positive Study Results Of Seven-Day Patch For PD
Industry Brief - GeNeuro/Servier Enter Partnership For GNbAC1 In MS
Industry Trend Analysis - New Copaxone Dose Will Soften Impact Of Generics On Teva's Revenues
Industry Brief - First MS Patients In US Receive Genzyme's Lemtrada Following FDA Approval
Industry Trend Analysis - Gilenya's Failure Will Not Deter Interest In Progressive MS
Industry Brief - Phase III Trial Initiated For Dalfampridine In Post-Stroke Walking Deficits
Industry Brief - Eisai Demonstrates Efficacy Of Investigational DORA In Sleep Initiation And Maintenance
Industry Brief - First Patients Enrolled In Xyrem Paediatric Narcolepsy Study
Industry Brief - Edgemont Extends Marketing Exclusivity In US For Forfivo XL
Industry Brief - Naurex' GLYX-13 Shows Robust And Sustained Antidepressant Effects In Phase IIb Study
Industry Brief - FDA Approves Labelling Update For Abilify Maintena
Industry Brief - Actavis Launches Guanfacine In US
Industry Brief - Consilient Health Launches Aripiprazole In UK
Industry Brief - FDA Accepts For Review sNDA For Deltoid Administration Of Abilify Maintena
Industry Trend Analysis - 2015 Will Bring Brexpiprazole's Approval And Patent Cliff For Otsuka
Industry Brief - AcelRx Receives CE Mark Approval For Zalviso
Industry Brief - Wraser Receives FDA Approval Of Trezix For Moderate-To-Moderately Severe Pain
Industry Brief - FDA Approves Two Higher Dosage Strengths Of Zubsolv
Industry Brief - Sunovion Submits sNDA For Aptiom As MT Treatment Of POS
Industry Trend Analysis - Brivaracetam Will Help UCB Maintain A Strong Position In Epilepsy
Industry Brief - Par Adds Name To Trokendi XR Patent Challengers
Industry Brief - RedHill Submits Bekinda MAA For Oncology Support
Industry Brief - Naurex Raises Funds To Advance NMDA Receptor Modulators In Depression/Other CNS Disorders
Industry Brief - Annexon Raises Funds For Novel Approach To Neurodegenerative/Autoimmune Diseases
Industry Brief - Evgen Seeking To Raise GBP20mn In IPO On AIM
Industry Brief - CNS Conferences - March 2015

Table Of Contents

CNS Drug News 15 DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.